NOT-FD-23-002: Notice to Extend the Letter of Intent and Application Due Date for RFA-FD-23-014- " In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required"

Notice to Extend the Letter of Intent and Application Due Date for RFA-FD-23-014- " In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required"

Notice Number:

NOT-FD-23-002

Key Dates

Release Date:

Related Announcements

RFA-FD-23-014 - In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required

Issued by

FOOD AND DRUG ADMINISTRATION (FDA)

Purpose

This Notice is to extend the Letter of Intent and Application Due Date for RFA-FD-23-014 - "In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required."

New Letter of Intent Due Date(s)

February 2, 2023

New Application Due Date(s)

April 3, 2023, by 11:59 PM Eastern Time.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.

Late applications will not be accepted for this FOA.

Inquiries

Please direct all inquiries to:

Shashi Malhotra
Food and Drug Administration
Office of Operations, Office of Finance Budget & Acquisitions
Office of Grants and Acquisition Services
Tel: 301-402-7592
Email: Shashi.Malhotra@fda.hhs.gov